Filtered By:
Nutrition: Vitamin K

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 1818 results found since Jan 2013.

Left ventricular thrombus in a patient with recurrent ischemic stroke events —The role of echocardiography
We present a patient with an ischemic stroke, and the cardiac ultrasound revealed a reduced ejection fraction and the presence of LV thrombus at the apex. The patient had no prior history of cardiovascular diseases. Even in a resource-limited setting, cardiac ultrasound is recommended to investigate stroke or transient ischemic attack events, especially in patients with a prior history of myocardial infarction. Although patients with LV thrombus should be treated with oral anticoagulants for at least 3  months, the role of direct oral anticoagulants and the optimal period of anticoagulation in this setting needs further investigation.
Source: Clinical Case Reports - May 2, 2023 Category: General Medicine Authors: Vasiliki Vanesa Stylianou, Vasiliki Tsampasian, Marios Pavlou, Panagiota Georgiou, Dimitrios Patestos, Lorentzos Kapetis, Vassilios S. Vassiliou, Christos Eftychiou, Michalis Tsielepis, George Bazoukis Tags: CASE REPORT Source Type: research

Po-04-216 patient enabled inr optimization : a multicenter prospective study
For patients using Vitamin K antagonists (VKA), maximizing time within the therapeutic range (TTR) reduces stroke, major hemorrhage, and death. Despite improvements in counselling and patient education, patients using Vitamin K antagonists have a poor TTR.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Muthiah Subramanian, Walli Mohammed, Hetan Shah, Sachin D. Yalagudri, Daljeet K. Saggu, Calambur Narasimhan Source Type: research

Cancers, Vol. 15, Pages 2574: Systematic Review and Meta-Analysis of Oral Anticoagulant Therapy in Atrial Fibrillation Cancer Patients
Conclusions: Anticoagulation with DOACs provides a higher safety profile with respect to VKAs in terms of stroke reduction and a relative bleeding reduction risk. Further studies are needed to better assess the optimal anticoagulation strategy in cancer patients with AF.
Source: Cancers - April 30, 2023 Category: Cancer & Oncology Authors: Alberto Cereda Stefano Lucreziotti Antonio Gabriele Franchina Alessandra Laricchia Valentina De Regibus Barbara Conconi Matteo Carl à Andrea Spangaro Matteo Rocchetti Luca Ponti Alessandro Minardi Elena Sala Giuseppe Massimo Sangiorgi Gabriele Tumminello Tags: Review Source Type: research

Oral anticoagulant switching in patients with atrial fibrillation: a scoping review
Conclusions OAC switching is common in patients with AF and patients often switch back to an OAC they have previously been on. There are aspects of OAC switching that have received little study, especially in switches from DOACs.
Source: BMJ Open - April 25, 2023 Category: General Medicine Authors: Adelakun, A. R., Turgeon, R. D., De Vera, M. A., McGrail, K., Loewen, P. S. Tags: Open access, Cardiovascular medicine Source Type: research

Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Systematic Review and Meta-analysis of Anticoagulation Strategy
ConclusionsCompared with VKAs, a DOAC-based strategy might represent an effective and safe strategy regarding all-cause mortality, major/life-threatening bleeding complications, and TEs in HCM patients with concomitant AF. However, further prospective studies are necessary to reinforce a DOAC-based anticoagulation strategy in this population.
Source: American Journal of Cardiovascular Drugs - April 15, 2023 Category: Cardiology Source Type: research

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
CONCLUSIONS: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.PMID:37042255 | DOI:10.1161/CIRCULATIONAHA.122.062752
Source: Circulation - April 12, 2023 Category: Cardiology Authors: Josephine Harrington Anthony P Carnicelli Kaiyuan Hua Lars Wallentin Manesh R Patel Stefan H Hohnloser Robert P Giugliano Keith A A Fox Ziad Hijazi Renato D Lopes Sean D Pokorney Hwanhee Hong Christopher B Granger Source Type: research

Factors influencing left ventricular thrombus resolution and its significance on clinical outcomes
ConclusionsThis study suggests that LVT resolution is an important predictor for favourable clinical outcomes. LVEF improvement failure interfered with LVT resolution and appeared to be a crucial factor for LVT recurrence. After LVT resolution, continuation of anticoagulation did not seem to impact LVT recurrence and the prognosis.
Source: ESC Heart Failure - April 4, 2023 Category: Cardiology Authors: Se ‐Eun Kim, Chan Joo Lee, Jaewon Oh, Seok‐Min Kang Tags: Original Article Source Type: research

Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis
ConclusionBased on current evidence, for stroke prevention and treatment in patients with AF, the most safe DOAC is edoxaban in terms of fatal bleeding; dabigatran in terms of major bleeding and intracranial hemorrhage and apixaban in terms of gastrointestinal bleeding. However, given the nature of indirect comparisons, more high-quality evidence from head-to-head comparisons is still needed to confirm them.
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research

Is There a Role for Vitamin K Antagonist in the Management of Atrial Fibrillation in 2023?
AbstractPurpose of ReviewTo address the following question: Are vitamin K antagonists (VKA) obsolete as stroke prevention therapy for patients with atrial fibrillation (AF) and thromboembolic risk factors?Recent FindingsA patient-level meta-analysis of the pivotal phase III randomized trials confirmed the favorable treatment effect of direct oral anticoagulants (DOAC) over VKA in multiple key patient subgroups. Among patients with AF and rheumatic heart disease (85% of whom had mitral stenosis), a randomized trial showed that rivaroxaban was not superior to VKA for stroke prevention. Caution should be exercised when prescr...
Source: Current Cardiology Reports - March 30, 2023 Category: Cardiology Source Type: research

Stroke in Atrial Fibrillation and Other Atrial Dysrhythmias
AbstractPurpose of ReviewAtrial fibrillation (AF) is a major risk factor for systemic embolism and ischaemic stroke. Furthermore, AF-related strokes are associated with higher mortality, greater disability, longer hospital stays and lower rates of hospital discharge than strokes caused by other reasons. The aim of this review to summarise the existing evidence on the association of AF with ischemic stroke and provide insights on the pathophysiological mechanisms and the clinical management of patients with AF in order to reduce the burden of ischemic stroke.Recent FindingsBeyond Virchow ’s triad, several pathophysiologic...
Source: Current Cardiology Reports - March 28, 2023 Category: Cardiology Source Type: research

Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study
CONCLUSIONS: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation.time in therapeutic range with <70%.PMID:36916815 | DOI:10.5543/tkda.2022.98455
Source: Turk Kardiyoloji Dernegi arsivi - March 14, 2023 Category: Cardiology Authors: Umut Kocaba ş I şıl Ergin Veysel Yavuz Selda Murat Ibrahim Özdemir Ömer Genç Cihan Alt ın Ha şim Tüner Bengisu Keskin Meri ç Ali Çoner Elif İlkay Yüce Bedrettin Boyraz Onur Aslan Ahmet Dal Taner Şen Ersin İbişoğlu Aslan Erdo ğan Mehmet Source Type: research